行情

MDGL

MDGL

Madrigal Pharms
NASDAQ

实时行情|Nasdaq Last Sale

68.73
-2.92
-4.08%
盘后: 68.73 0 0.00% 16:56 03/27 EDT
开盘
69.78
昨收
71.65
最高
73.60
最低
68.48
成交量
25.78万
成交额
--
52周最高
145.16
52周最低
60.86
市值
10.60亿
市盈率(TTM)
-12.6082
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MDGL价格均价为179.83,最高价位300.00,最低价为120.00。

EPS

MDGL 新闻

更多
  • 澳大利亚承诺在六个月投入1300亿澳元保障就业
  • 新浪财经 · 1小时前
  • 北欧富国66万人因疫情失业
  • 新浪财经 · 1小时前
  • 摩根大通称风险资产市场大多已过了最黑暗时期
  • 新浪财经 · 1小时前
  • 未雨绸缪 韩国12月曾举行应对假想疫情演习
  • 新浪财经 · 2小时前

所属板块

生物技术和医学研究
-2.44%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

MDGL 简况

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
展开

微牛提供Madrigal Pharmaceuticals Inc(NASDAQ-MDGL)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MDGL股票新闻,以帮助您做出投资决策。